29976 Federal Register / Vol. 66, No. 107 / Monday, June 4, 2001 / Notices

to make available to ACF pre-award

review and procurement documents,

such as request for proposals or

invitations for bids, independent cost

estimates, etc.

Note: Whenever the applicant intends to

delegate part of the project to another agency,

the applicant must provide a detailed budget

and budget narrative for each delegate

agency, by agency title, along with the

required supporting information referred to

in these instructions.

6g. Other:

Enter the total of all other costs. Such

costs, where applicable and appropriate,

may include but are not limited to

insurance, food, medical and dental

costs (noncontractual), professional

services costs, space and equipment

rentals, printing and publication,

computer use, training costs, such as

tuition and stipends, staff development

costs, and administrative costs.

Justification: Provide computations, a

narrative description and a justification

for each cost under this category.

6h. Indirect Charges:

Description: Total amount of indirect

costs. This category should be used only

when the applicant currently has an

indirect cost rate approved by the

Department of Health and Human

Services (HHS) or another cognizant

Federal agency.

Justification: An applicant that will

charge indirect costs to the grant must

enclose a copy of the current rate

agreement. If the applicant organization

is in the process of initially developing

or renegotiating a rate, it should

immediately upon notification that an

award will be made, develop a tentative

indirect cost rate application based on

its most recently completed fiscal year

in accordance with the principles set

forth in the cognizant agency’s

guidelines for establishing indirect cost

rates, and submit it to the cognizant

agency. Applicants awaiting approval of

their indirect cost applications may also

request indirect costs. It should be noted

that when an indirect cost rate is

requested, those costs included in the

indirect cost pool should not also be

charged as direct costs to the grant.

Also, if the applicant is requesting a rate

which is less than what is allowed

under the program, the authorized

representative of the applicant

organization must submit a signed

acknowledgement that the applicant is

accepting a lower rate than allowed.

6i. Program Income:

Description: The estimated amount of

income, if any, expected to be generated

from this project.

Justification: Describe the nature,

source and anticipated use of program

income in the budget or refer to the

pages in the application which contain

this information.

B. Other Forms, Assurances, and

Certifications

Standard Form 424: Application for

Federal Assistance

Standard Form 424A: Budget

Information

Standard Form 424B: Assurances—NonConstruction Programs

Certification Regarding Debarment

Certification Regarding Drug-Free

Workplace

Form LLL: Disclosure of Lobbying

Certification Regarding Environmental

Tobacco Smoke

State Single Point of Contact (SPOC)

Listing

All forms are available online at:

http://www.acf.dhhs.gov/programs/ofs/

grants/form.htm.

The SPOC listing is available on line

at http://www.whitehouse.gov/omb/

grants/spoc.html.

Dated: May 29, 2001.

James A. Harrell,

Acting Commissioner, Administration on

Children, Youth and Families.

[FR Doc. 01–13921 Filed 6–1–01; 8:45 am]

BILLING CODE 4184–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

Health Resources and Services

Administration

Agency Information Collection

Activities: Proposed Collection:

Comment Request

In compliance with the requirement

for opportunity for public comment on

proposed data collection projects

(section 3506(c)(2)(A) of Title 44, United

States Code, as amended by the

Paperwork Reduction Act of 1995,

Public Law 104–13), the Health

Resources and Services Administration

(HRSA) publishes periodic summaries

of proposed projects being developed

for submission to OMB under the

Paperwork Reduction Act of 1995. To

request more information on the

proposed project or to obtain a copy of

the data collection plans and draft

instruments, call the HRSA Reports

Clearance Officer on (301) 443–1129.

Comments are invited on: (a) Whether

the proposed collection of information

is necessary for the proper performance

of the functions of the agency, including

whether the information shall have

practical utility; (b) the accuracy of the

agency’s estimate of the burden of the

proposed collection of information; (c)

ways to enhance the quality, utility, and

clarity of the information to be

collected; and (d) ways to minimize the

burden of the collection of information

on respondents, including through the

use of automated collection techniques

or other forms of information

technology.

Proposed Project: The Health

Education Assistance Loan (HEAL)

Program: Refinancing Loan Application/

Promissory Note (OMB No. 0915–

0227)—Revision—The HEAL Program

allows borrowers who graduated or

separated from school to refinance all of

their HEAL loans into one new HEAL

loan, often at better rates and terms than

their original HEAL loans. The HEAL

program originally provided new

federally-insured loans to students in

schools of allopathic medicine,

osteopathic medicine, dentistry,

veterinary medicine, optometry,

podiatric medicine, pharmacy, public

health, graduate students in health

administration or clinical psychology

through September 30, 1998. Eligible

lenders, such as banks, savings and loan

associations, credit unions, pension

funds, insurance companies, State

agencies, and HEAL schools are insured

by the Federal Government against loss

due to the borrower’s death, disability,

bankruptcy, and default. The basic

purpose of the program was to assure

the availability of funds for loans to

eligible students who needed to borrow

money to pay for their educational

costs.

The HEAL refinancing loan

application/promissory note is being

used by lenders to refinance borrower’s

original HEAL loans into one new

refinanced loan. Due to the success of

this form and desire to reduce

application processing time, many

lenders have automated this form by

and taking pertinent application

information over the telephone and

sending the completed form to the

borrower for their review and signature.

The estimate of burden for the

refinancing loan application/promissory

note form per year is as follows:

Federal Register / Vol. 66, No. 107 / Monday, June 4, 2001 / Notices 29977

Type of respondent Number of respondents

Responses

per respondent

Total number

of responses

Burden per responses (minutes)

Total burden

hours

Applicants ............................................................................. 1,850 1 1,850 12 370

Lenders ................................................................................ 9 206 1,854 30 927

Total .............................................................................. 1,859 ........................ 3,704 ........................ 1,297

Send comments to Susan G. Queen,

Ph.D., HRSA Reports Clearance Officer,

Room 14–33, Parklawn Building, 5600

Fishers Lane, Rockville, MD 20857.

Written comments should be received

within 60 days of this notice.

Dated: May 25, 2001.

Jane M. Harrison,

Director, Division, of Policy Review and

Coordination.

[FR Doc. 01–13850 Filed 6–1–01; 8:45 am]

BILLING CODE 4160–15–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by writing

to the indicated licensing contact at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7057; fax: 301/402–0220. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

PRAC & PRAC–Y: Small Nuclear

Proteins Found in Prostate and Colon

Cancer, and Uses Thereof

Ira Pastan et al. (NCI)

DHHS Reference No. E–053–01/0, filed

09 Apr 2001

Licensing Contact: Richard Rodriguez;

301/496–7056, ext. 287; e-mail:

rodrigur@od.nih.gov

Prostate cancer is the most commonly

diagnosed cancer and the second

leading cause of cancer death in males

in the United States. Currently, there are

no curative therapies available for this

cancer and therefore, novel approaches

are needed to treat this disease. The

present invention claims a small,

nuclear protein, PRAC (Prostate/Rectum

And Colon Protein) that could be used

to diagnose and/or treat prostate or

colon cancers. In conjunction with the

composition of matter claims, defined

methods of use might include: (1)

Immunogenic fragments to elicit T cell

responses against cells that express

PRAC; (2) gene therapy applications

through the use of appropriate

expression vectors containing the

nucleic acid sequences of PRAC; (3)

detection and potential staging of

cancers expressing PRAC. These

disclosed technologies could provide

new and exciting methodologies to treat

prostate and/or colon cancer.

Biologically Active Macrolides,

Compositions and Uses Thereof

Michael R. Boyd (NCI), Kirk R.

Gustafson (NCI), and Charles L.

Cantrell (USDA)

DHHS Reference No. E–203–00/0, filed

24 Jul 2000

Licensing Contact: Elaine White; 301/

496–7056, ext. 282; e-mail:

gesee@od.nih.gov

The current invention embodies the

identification of a novel class of potent

vacuolar-type (H+)-ATPase-inhibitory

compounds. Vacuolar-type (H+)-

ATPases are present in many tissues

and cells of the body and are involved

in the maintenance of various

physiological functions. The

modification of these functions, via

inhibition of vacuolar-type (H+)-

ATPases, may represent an effective

means of treating various disease states,

including Alzheimer’s disease,

glaucoma, and osteoporosis. In addition,

these inhibitors may also be of

particular value for use against cancer,

as vacuolar-type (H+)-ATPases have

been implicated in processes relating to

cellular proliferation, angiogenesis,

tumor cell invasiveness, metastasis, and

drug resistance.

Dated: May 24, 2001.

Jack Spiegel,

Director, Division of Technology,

Development and Transfer, Office of

Technology Transfer, National Institutes of

Health.

[FR Doc. 01–13886 Filed 6–1–01; 8:45 am]

BILLING CODE 4140–01–P

DEPARTMENT OF HEALTH AND

HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions;

Availability for Licensing

AGENCY: National Institutes of Health,

Public Health Service, DHHS.

ACTION: Notice.

SUMMARY: The inventions listed below

are owned by agencies of the U.S.

Government and are available for

licensing in the U.S. in accordance with

35 U.S.C. 207 to achieve expeditious

commercialization of results of

federally-funded research and

development. Foreign patent

applications are filed on selected

inventions to extend market coverage

for companies and may also be available

for licensing.

ADDRESSES: Licensing information and

copies of the U.S. patent applications

listed below may be obtained by

contacting Peter A. Soukas, J.D., at the

Office of Technology Transfer, National

Institutes of Health, 6011 Executive

Boulevard, Suite 325, Rockville,

Maryland 20852–3804; telephone: 301/

496–7056 ext. 268; fax: 301/402–0220;

e-mail: soukasp@od.nih.gov. A signed

Confidential Disclosure Agreement will

be required to receive copies of the

patent applications.

Identification of New Small RNAs and

ORFs

Susan Gottesman (NCI), Gisela Storz

(NICHD), Karen Wassarman (NICHD),

Francis Repoila (NCI), Carsten

Rosenow (EM)

DHHS Reference No. E–072–01/0, filed

01 Feb 2001

The inventors have isolated a number

of previously unknown sRNAs found in

E. coli. Previous scientific publications

by the inventors and others regarding